Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Chemoradiation With Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer: A Real-Word Multi-center Study

NCT05148767 is registered in ClinicalTrials.gov with Zhejiang Cancer Hospital as lead sponsor.

NCT NCT05148767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05148767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Chemoradiation With Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer: A Real-Word Multi-center Study
Lead sponsor
Zhejiang Cancer Hospital
Phase
Phase 4
Overall status
Recruiting
Start date
January 1, 2022
Completion date
December 30, 2026
Enrollment
606 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer stage iii